Company news

AnaptysBio, Inc. news in 2022

AnaptysBio, Inc.'s news releases, calls and decks from 2022, newest first.

View company

AnaptysBio- and GSK-partnered immuno-oncology agent JEMPERLI (dostarlimab-gxly) meets primary endpoint in Phase 3 RUBY trial in primary advanced or recurrent endometrial cancer

December 1, 2022

AnaptysBio to Participate at the Piper Sandler 34th Annual Healthcare Conference

November 20, 2022

AnaptysBio to Participate in Upcoming November Investor Conferences

November 8, 2022

AnaptysBio Announces Third Quarter 2022 Financial Results and Provides Pipeline Update

November 7, 2022

AnaptysBio and GSK-partnered immuno-oncology agents JEMPERLI (dostarlimab-gxly) and cobolimab show positive progress in two separate non-small cell lung cancer trials

October 4, 2022

AnaptysBio Announces Sale of Zejula Royalties for Up To $45 Million

September 11, 2022

AnaptysBio Reports HARP Phase 2 Top-Line Data of Imsidolimab in Moderate-to-Severe Hidradenitis Suppurativa

August 30, 2022

AnaptysBio Announces Second Quarter 2022 Financial Results and Provides Pipeline Update

August 7, 2022

AnaptysBio to Participate at the 2022 Wedbush PacGrow Healthcare Virtual Conference

August 4, 2022

AnaptysBio to Participate at the 2022 Jefferies Healthcare Conference

June 1, 2022

AnaptysBio Announces First Quarter 2022 Financial Results and Provides Pipeline Update

May 3, 2022

AnaptysBio Announces Positive ANB032 (anti-BTLA agonist) Top-Line Phase 1 Data and Provides Pipeline Updates

April 26, 2022

AnaptysBio Appoints Daniel Faga As Interim Chief Executive Officer

March 20, 2022

AnaptysBio Reports Imsidolimab ACORN Phase 2 Clinical Trial Data in Moderate-to-Severe Acne

March 13, 2022

AnaptysBio Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Pipeline Update

March 6, 2022

AnaptysBio To Present at the 40th Annual J.P. Morgan Healthcare Conference

January 4, 2022

Decks in 2022